Correction to: The actions of relaxin on the human cardiovascular system (Br J Pharmacol, (2017), 174, 10, (933-949), 10.1111/bph.13523);The actions of relaxin on the human cardiovascular system

British Journal of Pharmacology

Volumn 174, Issue 10, 2017, Pages 933-949

  Sarwar, Mohsin ^a   Du, Xiao Jun ^b   Dschietzig, Thomas B ^c,d,e   Summers, Roger J ^a  

^a MONASH UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c IMMUNDIAGNOSTIK AG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Relaxera Pharmazeutische Gesellschaft mbH Co KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ENDOTHELIN RECEPTOR; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECEPTOR PROTEIN; RELAXIN; RELAXIN FAMILY PEPTIDE RECEPTOR 1; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ANGIOGENESIS; ANTIARRHYTHMIC ACTIVITY; ARTICLE; BLOOD VESSEL; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CARDIOMYOPATHY; CARDIOVASCULAR SYSTEM; CELL INTERACTION; DRUG EFFECT; ENDOTHELIUM CELL; HEART ARRHYTHMIA; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART MUSCLE FIBROSIS; HORMONE ACTION; HUMAN; HYPERTENSION; IN VIVO STUDY; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VEIN DILATATION; CARDIOVASCULAR DISEASE; DRUG EFFECTS;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; RELAXIN;

EID: 84978269177     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.14111     Document Type: Erratum

References (169)

1. Ahmad N, Wang W, Nair R, Kapila S (2012). Relaxin induces matrix-metalloproteinases-9 and -13 via RXFP1: induction of MMP-9 involves the PI3K, ERK, Akt and PKC-zeta pathways. Mol Cell Endocrinol 363: 46–61.
2. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
3. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: G Protein-Coupled Receptors. Br J Pharmacol 172: 5744–5869.
4. Alexander SPH, Cidlowski JA, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015c). The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. Br J Pharmacol 172: 5956–5978.
5. Alexiou K, Wilbring M, Matschke K, Dschietzig T (2013). Relaxin protects rat lungs from ischemia–reperfusion injury via inducible NO synthase: role of ERK-1/2, PI3K, and forkhead transcription factor FKHRL1. PLoS One 8: e75592.
6. Bani D, Baronti R, Vannacci A, Bigazzi M, Sacchi TB, Mannaioni PF et al. (2002). Inhibitory effects of relaxin on human basophils activated by stimulation of the Fc epsilon receptor. The role of nitric oxide. Int Immunopharmacol 2: 1195–1204.
7. Bani D, Bigazzi M, Masini E, Bani G, Sacchi TB (1995a). Relaxin depresses platelet aggregation: in vitro studies on isolated human and rabbit platelets. Lab Invest 73: 709–716.
8. Bani D, Failli P, Bello MG, Thiemermann C, Bani Sacchi T, Bigazzi M et al. (1998a). Relaxin activates the L-arginine-nitric oxide pathway in vascular smooth muscle cells in culture. Hypertension 31: 1240–1247.
9. Bani D, Masini E, Bello MG, Bigazzi M, Sacchi TB (1995b). Relaxin activates the L-arginine-nitric oxide pathway in human breast cancer cells. Cancer Res 55: 5272–5275.
10. Bani D, Masini E, Bello MG, Bigazzi M, Sacchi TB (1998b). Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart. Am J Pathol 152: 1367–1376.
11. Bani-Sacchi T, Bigazzi M, Bani D, Mannaioni PF, Masini E (1995). Relaxin-induced increased coronary flow through stimulation of nitric oxide production. Br J Pharmacol 116: 1589–1594.
12. Bathgate RA, Halls ML, van der Westhuizen ET, Callander GE, Kocan M, Summers RJ (2013). Relaxin family peptides and their receptors. Physiol Rev 93: 405–480.
13. Bathgate RA, Lekgabe ED, McGuane JT, Su Y, Pham T, Ferraro T et al. (2008). Adenovirus-mediated delivery of relaxin reverses cardiac fibrosis. Mol Cell Endocrinol 280: 30–38.
14. Bennett RG (2009). Relaxin and its role in the development and treatment of fibrosis. Transl Res 154: 1–6.
15. Bitto A, Irrera N, Minutoli L, Calo M, Lo Cascio P, Caccia P et al. (2013). Relaxin improves multiple markers of wound healing and ameliorates the disturbed healing pattern of genetically diabetic mice. Clin Sci 125: 575–585.
16. Boccalini G, Sassoli C, Formigli L, Bani D, Nistri S (2015). Relaxin protects cardiac muscle cells from hypoxia/reoxygenation injury: involvement of the Notch-1 pathway. FASEB J 29: 239–249.
17. Bonner JS, Lantier L, Hocking KM, Kang L, Owolabi M, James FD et al. (2013). Relaxin treatment reverses insulin resistance in mice fed a high-fat diet. Diabetes 62: 3251–3260.
18. Braam B, Joles JA, Danishwar AH, Gaillard CA (2014). Cardiorenal syndrome–current understanding and future perspectives. Nat Rev Nephrol 10: 48–55.
19. Brecht A, Bartsch C, Baumann G, Stangl K, Dschietzig T (2011). Relaxin inhibits early steps in vascular inflammation. Regul Pept 166: 76–82.
20. Bueno OF, Molkentin JD (2002). Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 91: 776–781.
21. Carey RM (2005). Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension 45: 840–844.
22. Chow BS, Chew EG, Zhao C, Bathgate RA, Hewitson TD, Samuel CS (2012). Relaxin signals through a RXFP1–pERK–nNOS–NO–cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS. PLoS One 7: e42714.
23. Chow BS, Kocan M, Bosnyak S, Sarwar M, Wigg B, Jones ES et al. (2014). Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis. Kidney Int 86: 75–85.
24. Collino M, Rogazzo M, Pini A, Benetti E, Rosa AC, Chiazza F et al. (2013). Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury. J Cell Mol Med 17: 1494–1505.
25. Conrad KP, Debrah DO, Novak J, Danielson LA, Shroff SG (2004). Relaxin modifies systemic arterial resistance and compliance in conscious, nonpregnant rats. Endocrinology 145: 3289–3296.
26. Conrad KP, Novak J (2004). Emerging role of relaxin in renal and cardiovascular function. Am J Physiol Regul Integr Comp Physiol 287: R250–R261.
27. Conrad KP, Shroff SG (2011). Effects of relaxin on arterial dilation, remodeling, and mechanical properties. Curr Hypertens Rep 13: 409–420.
28. Cotter G, Voors AA, Weatherley BD, Pang PS, Teerlink JR, Filippatos G et al. (2010). Acute heart failure clinical drug development: from planning to proof of activity to phase III. Cardiology 116: 292–301.
29. Coulson CC, Thorp JM Jr, Mayer DC, Cefalo RC (1996). Central hemodynamic effects of recombinant human relaxin in the isolated, perfused rat heart model. Obstet Gynecol 87: 610–612.
30. Danielson LA, Sherwood OD, Conrad KP (1999). Relaxin is a potent renal vasodilator in conscious rats. J Clin Invest 103: 525–533.
31. de Wit C, Boettcher M, Schmidt VJ (2008). Signaling across myoendothelial gap junctions–fact or fiction? Cell Commun Adhes 15: 231–245.
32. Debrah DO, Conrad KP, Danielson LA, Shroff SG (2005a). Effects of relaxin on systemic arterial hemodynamics and mechanical properties in conscious rats: sex dependency and dose response. J Appl Physiol 98: 1013–1020.
33. Debrah DO, Conrad KP, Jeyabalan A, Danielson LA, Shroff SG (2005b). Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats. Hypertension 46: 745–750.
34. Debrah DO, Novak J, Matthews JE, Ramirez RJ, Shroff SG, Conrad KP (2006). Relaxin is essential for systemic vasodilation and increased global arterial compliance during early pregnancy in conscious rats. Endocrinology 147: 5126–5131.
35. Dschietzig T, Alexiou K, Kinkel HT, Baumann G, Matschke K, Stangl K (2011). The positive inotropic effect of relaxin-2 in human atrial myocardium is preserved in end-stage heart failure: role of G(i)-phosphoinositide-3 kinase signaling. J Card Fail 17: 158–166.
36. Dschietzig T, Bartsch C, Baumann G, Stangl K (2009a). RXFP1-inactive relaxin activates human glucocorticoid receptor: further investigations into the relaxin-GR pathway. Regul Pept 154: 77–84.
37. Dschietzig T, Bartsch C, Kinkel T, Baumann G, Stangl K (2005). Myocardial relaxin counteracts hypertrophy in hypertensive rats. Ann N Y Acad Sci 1041: 441–443.
38. Dschietzig T, Bartsch C, Richter C, Laule M, Baumann G, Stangl K (2003). Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kB. Circ Res 92: 32–40.
39. Dschietzig T, Bartsch C, Stangl V, Baumann G, Stangl K (2004). Identification of the pregnancy hormone relaxin as glucocorticoid receptor agonist. FASEB J 18: 1536–1538.
40. Dschietzig T, Brecht A, Bartsch C, Baumann G, Stangl K, Alexiou K (2012). Relaxin improves TNF-alpha-induced endothelial dysfunction: the role of glucocorticoid receptor and phosphatidylinositol 3-kinase signalling. Cardiovasc Res 95: 97–107.
41. Dschietzig T, Richter C, Bartsch C, Bohme C, Heinze D, Ott F et al. (2001a). Flow-induced pressure differentially regulates endothelin-1, urotensin II, adrenomedullin, and relaxin in pulmonary vascular endothelium. Biochem Biophys Res Commun 289: 245–251.
42. Dschietzig T, Richter C, Bartsch C, Laule M, Armbruster FP, Baumann G et al. (2001b). The pregnancy hormone relaxin is a player in human heart failure. FASEB J 15: 2187–2195.
43. Dschietzig T, Teichman S, Unemori E, Wood S, Boehmer J, Richter C et al. (2009b). Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail 15: 182–190.
44. Du XJ, Hewitson TD, Nguyen MN, Samuel CS (2014). Therapeutic effects of serelaxin in acute heart failure. Circ J 78: 542–552.
45. Du XJ, Samuel CS, Gao XM, Zhao L, Parry LJ, Tregear GW (2003). Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender-specific phenotype. Cardiovasc Res 57: 395–404.
46. Dukes JW, Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS et al. (2015). Ventricular ectopy as a predictor of heart failure and death. J Am Coll Cardiol 66: 101–109.
47. Edouard DA, Pannier BM, London GM, Cuche JL, Safar ME (1998). Venous and arterial behavior during normal pregnancy. Am J Physiol 274: H1605–H1612.
48. Eschenhagen T, Mende U, Nose M, Schmitz W, Scholz H, Haverich A et al. (1992). Increased messenger RNA level of the inhibitory G protein alpha subunit Gi alpha-2 in human end-stage heart failure. Circ Res 70: 688–696.
49. Failli P, Nistri S, Quattrone S, Mazzetti L, Bigazzi M, Sacchi TB et al. (2002). Relaxin up-regulates inducible nitric oxide synthase expression and nitric oxide generation in rat coronary endothelial cells. FASEB J 16: 252–254.
50. Felker GM, Teerlink JR, Butler J, Hernandez AF, Miller AB, Cotter G et al. (2014). Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. J Am Coll Cardiol 64: 1591–1598.
51. Fernandez-Patron C, Radomski MW, Davidge ST (1999). Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85: 906–911.
52. Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST (2000). Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 87: 670–676.
53. Fisher C, MacLean M, Morecroft I, Seed A, Johnston F, Hillier C et al. (2002). Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart? Circulation 106: 292–295.
54. Fisher CJ (2009). Relaxin: a new cardiovascular hormone in humans? Comparative potency and mechanisms of action. MD thesis Dept Medicine and Therapeutics. Glasgow University.
55. Formigli L, Francini F, Tani A, Squecco R, Nosi D, Polidori L et al. (2005). Morphofunctional integration between skeletal myoblasts and adult cardiomyocytes in coculture is favored by direct cell–cell contacts and relaxin treatment. Am J Physiol Cell Physiol 288: C795–C804.
56. Formigli L, Perna AM, Meacci E, Cinci L, Margheri M, Nistri S et al. (2007). Paracrine effects of transplanted myoblasts and relaxin on post-infarction heart remodelling. J Cell Mol Med 11: 1087–1100.
57. Garber SL, Mirochnik Y, Brecklin C, Slobodskoy L, Arruda JA, Dunea G (2003). Effect of relaxin in two models of renal mass reduction. Am J Nephrol 23: 8–12.
58. Garber SL, Mirochnik Y, Brecklin CS, Unemori EN, Singh AK, Slobodskoy L et al. (2001). Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int 59: 876–882.
59. Gelman S (2008). Venous function and central venous pressure: a physiologic story. Anesthesiology 108: 735–748.
60. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L et al. (2006). Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296: 2217–2226.
61. Gooi JH, Richardson ML, Jelinic M, Girling JE, Wlodek ME, Tare M et al. (2013). Enhanced uterine artery stiffness in aged pregnant relaxin mutant mice is reversed with exogenous relaxin treatment. Biol Reprod 89: 18.
62. Greene SJ, Gheorghiade M (2014). Matching mechanism of death with mechanism of action: considerations for drug development for hospitalized heart failure. J Am Coll Cardiol 64: 1599–1601.
63. Gu HP, Lin S, Xu M, Yu HY, Du XJ, Zhang YY et al. (2012). Up-regulating relaxin expression by G-quadruplex interactive ligand to achieve antifibrotic action. Endocrinology 153: 3692–3700.
64. Haase N, Rugor J, Przybyl L, Qadri F, Muller DN, Dechend R (2014). Relaxin does not improve angiotensin II-induced target-organ damage. PLoS One 9: e93743.
65. Halls ML, Bathgate RA, Summers RJ (2006). Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms. Mol Pharmacol 70: 214–226.
66. Halls ML, Bathgate RA, Sutton SW, Dschietzig TB, Summers RJ (2015). International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1–4, the receptors for relaxin family peptides. Pharmacol Rev 67: 389–440.
67. Halls ML, Hewitson TD, Moore XL, Du XJ, Bathgate RA, Summers RJ (2009). Relaxin activates multiple cAMP signaling pathway profiles in different target cells. Ann N Y Acad Sci 1160: 108–111.
68. Han X, Habuchi Y, Giles WR (1994). Relaxin increases heart rate by modulating calcium current in cardiac pacemaker cells. Circ Res 74: 537–541.
69. Heeg MHJ, Koziolek MJ, Vasko R, Schaefer L, Sharma K, Muller GA et al. (2005). The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int 68: 96–109.
70. Ho TY, Yan W, Bagnell CA (2007). Relaxin-induced matrix metalloproteinase-9 expression is associated with activation of the NF-kB pathway in human THP-1 cells. J Leukoc Biol 81: 1303–1310.
71. Hogan CJ, Ward KR, Franzen DS, Rajendran B, Thacker LR (2012a). Sublingual tissue perfusion improves during emergency treatment of acute decompensated heart failure. Am J Emerg Med 30: 872–880.
72. Hogan CJ, Ward KR, Kontos MC, Thacker LR, Pittman R (2012b). Peripheral tissue oxygenation improves during ED treatment of acute heart failure. Am J Emerg Med 30: 196–202.
73. Horton JS, Yamamoto SY, Bryant-Greenwood GD (2011). Relaxin modulates proinflammatory cytokine secretion from human decidual macrophages. Biol Reprod 85: 788–797.
74. Hossain MA, Man BC, Zhao C, Xu Q, Du XJ, Wade JD et al. (2011). H3 relaxin demonstrates antifibrotic properties via the RXFP1 receptor. Biochemistry 50: 1368–1375.
75. Houslay MD, Baillie GS, Maurice DH (2007). cAMP-specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 100: 950–966.
76. Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD et al. (2002). Activation of orphan receptors by the hormone relaxin. Science 295: 671–674.
77. Huang X, Cheng Z, Sunga J, Unemori E, Zsebo K (2001). Systemic administration of recombinant human relaxin (RHRLX) ameliorates the acute cyclosporine nephrotoxicity in rats. J Heart Lung Transplant 20: 253.
78. Huang X, Gai Y, Yang N, Lu B, Samuel CS, Thannickal VJ et al. (2011). Relaxin regulates myofibroblast contractility and protects against lung fibrosis. Am J Pathol 179: 2751–2765.
79. Januzzi JL Jr, Filippatos G, Nieminen M, Gheorghiade M (2012). Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. Eur Heart J 33: 2265–2271.
80. Jelinic M, Leo CH, Post Uiterweer ED, Sandow SL, Gooi JH, Wlodek ME et al. (2014). Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment. FASEB J 28: 275–287.
81. Jelinic M, Tare M, Conrad KP, Parry LJ (2015). Differential effects of relaxin deficiency on vascular aging in arteries of male mice. Age 37: 9803.
82. Jeyabalan A, Novak J, Danielson LA, Kerchner LJ, Opett SL, Conrad KP (2003). Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries. Circ Res 93: 1249–1257.
83. Kaftanovskaya EM, Huang Z, Lopez C, Conrad K, Agoulnik AI (2015). Conditional deletion of the relaxin receptor gene in cells of smooth muscle lineage affects lower reproductive tract in pregnant mice. Biol Reprod 92: 91.
84. Kakouris H, Eddie LW, Summers RJ (1992). Cardiac effects of relaxin in rats. Lancet 339: 1076–1078.
85. Kapila S, Xie Y, Wang W (2009). Induction of MMP-1 (collagenase-1) by relaxin in fibrocartilaginous cells requires both the AP-1 and PEA-3 promoter sites. Orthod Craniofac Res 12: 178–186.
86. Kawanabe Y, Nauli SM (2011). Endothelin. Cell Mol Life Sci 68: 195–203.
87. Kerchner LJ, Novak J, Hanley-Yanez K, Doty KD, Danielson LA, Conrad KP (2005). Evidence against the hypothesis that endothelial endothelin B receptor expression is regulated by relaxin and pregnancy. Endocrinology 146: 2791–2797.
88. Kern A, Agoulnik AI, Bryant-Greenwood GD (2007). The low-density lipoprotein class A module of the relaxin receptor (leucine-rich repeat containing G-protein coupled receptor 7): its role in signaling and trafficking to the cell membrane. Endocrinology 148: 1181–1194.
89. Kiselyov K, Shin DM, Muallem S (2003). Signalling specificity in GPCR-dependent Ca2+ signalling. Cell Signal 15: 243–253.
90. Kloner RA (2011). No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Ther 16: 244–250.
91. Kompa AR, Samuel CS, Summers RJ (2002). Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin. Br J Pharmacol 137: 710–718.
92. Kotecha D, Piccini JP (2015). Atrial fibrillation in heart failure: what should we do? Eur Heart J 36: 3250–3257.
93. Krajnc-Franken MA, van Disseldorp AJ, Koenders JE, Mosselman S, van Duin M, Gossen JA (2004). Impaired nipple development and parturition in LGR7 knockout mice. Mol Cell Biol 24: 687–696.
94. Lauten A, Ferrari M, Goebel B, Rademacher W, Schumm J, Uth O et al. (2011). Microvascular tissue perfusion is impaired in acutely decompensated heart failure and improves following standard treatment. Eur J Heart Fail 13: 711–717.
95. Lee HY, Zhao S, Fields PA, Sherwood OD (2005). The extent to which relaxin promotes proliferation and inhibits apoptosis of cervical epithelial and stromal cells is greatest during late pregnancy in rats. Endocrinology 146: 511–518.
96. Lekgabe ED, Kiriazis H, Zhao C, Xu Q, Moore XL, Su Y et al. (2005). Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 46: 412–418.
97. Leo CH, Jelinic M, Gooi JH, Tare M, Parry LJ (2014a). A vasoactive role for endogenous relaxin in mesenteric arteries of male mice. PLoS One 9: e107382.
98. Leo CH, Jelinic M, Parkington HC, Tare M, Parry LJ (2014b). Acute intravenous injection of serelaxin (recombinant human relaxin-2) causes rapid and sustained bradykinin-mediated vasorelaxation. J Am Heart Assoc 3: e000493.
99. Li Y, Brookes ZL, Kaufman S (2005). Acute and chronic effects of relaxin on vasoactivity, myogenic reactivity and compliance of the rat mesenteric arterial and venous vasculature. Regul Pept 132: 41–46.
100. Lodhi RS, Nakabayashi K, Suzuki K, Yamada AY, Hazama R, Ebina Y et al. (2013). Relaxin has anti-apoptotic effects on human trophoblast-derived HTR-8/SV neo cells. Gynecol Endocrinol 29: 1051–1054.
101. Ma JF, Liu L, Yang WJ, Zang LN, Xi YM (2013a). RNAi-mediated knockdown of relaxin decreases in vitro proliferation and invasiveness of osteosarcoma MG-63 cells by inhibition of MMP-9. Eur Rev Med Pharmacol Sci 17: 1102–1109.
102. Ma JF, Von Kalle M, Plautz Q, -M Xu F, Singh L, Wang L (2013b). Relaxin promotes in vitro tumour growth, invasion and angiogenesis of human Saos-2 osteosarcoma cells by AKT/VEGF pathway. Eur Rev Med Pharmacol Sci 17: 1345–1350.
103. Masini E, Bani D, Bello MG, Bigazzi M, Mannaioni PF, Sacchi TB (1997). Relaxin counteracts myocardial damage induced by ischemia–reperfusion in isolated guinea pig hearts: evidence for an involvement of nitric oxide. Endocrinology 138: 4713–4720.
104. Masini E, Di Bello MG, Bani D, Bigazzi M, Bani Sacchi T, Mannaioni PF (1995). Relaxin inhibits histamine release from mast cells: involvement of nitric oxide production. Inflamm Res 44 (Suppl 1): S12–S13.
105. Masini E, Nistri S, Vannacci A, Bani Sacchi T, Novelli A, Bani D (2004). Relaxin inhibits the activation of human neutrophils: involvement of the nitric oxide pathway. Endocrinology 145: 1106–1112.
106. Masini E, Zagli G, Ndisang JF, Solazzo M, Mannaioni PF, Bani D (2002). Protective effect of relaxin in cardiac anaphylaxis: involvement of the nitric oxide pathway. Br J Pharmacol 137: 337–344.
107. Masterson R, Hewitson TD, Kelynack K, Martic M, Parry L, Bathgate R et al. (2004). Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro. Nephrol Dial Transplant 19: 544–552.
108. Matsubara H (1998). Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 83: 1182–1191.
109. McGuane JT, Danielson LA, Debrah JE, Rubin JP, Novak J, Conrad KP (2011a). Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans. Hypertension 57: 1151–1160.
110. McGuane JT, Debrah JE, Sautina L, Jarajapu YP, Novak J, Rubin JP et al. (2011b). Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology 152: 2786–2796.
111. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH et al. (2013a). Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 61: 196–206.
112. Metra M, Ponikowski P, Cotter G, Davison BA, Felker GM, Filippatos G et al. (2013b). Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. Eur Heart J 34: 3128–3136.
113. Mologni L, Sala E, Cazzaniga S, Rostagno R, Kuoni T, Puttini M et al. (2006). Inhibition of RET tyrosine kinase by SU5416. J Mol Endocrinol 37: 199–212.
114. Mookerjee I, Hewitson TD, Halls ML, Summers RJ, Mathai ML, Bathgate RA et al. (2009). Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J 23: 1219–1229.
115. Moore XL, Su Y, Fan Y, Zhang YY, Woodcock EA, Dart AM et al. (2014). Diverse regulation of cardiac expression of relaxin receptor by α1- and β1-adrenoceptors. Cardiovasc Drugs Ther 28: 221–228.
116. Moore XL, Tan SL, Lo CY, Fang L, Su YD, Gao XM et al. (2007). Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes. Endocrinology 148: 1582–1589.
117. Ng HH, Jelinic M, Parry LJ, Leo CH (2015). Increased superoxide production and altered nitric oxide-mediated relaxation in the aorta of young but not old male relaxin-deficient mice. Am J Physiol Heart Circ Physiol 309: H285–H296.
118. Nguyen BT, Dessauer CW (2005a). Relaxin stimulates cAMP production in MCF-7 cells upon overexpression of type V adenylyl cyclase. Ann N Y Acad Sci 1041: 296–299.
119. Nguyen BT, Dessauer CW (2005b). Relaxin stimulates protein kinase C z translocation: requirement for cyclic adenosine 3′,5′-monophosphate production. Mol Endocrinol 19: 1012–1023.
120. Nistri S, Cinci L, Perna AM, Masini E, Mastroianni R, Bani D (2008). Relaxin induces mast cell inhibition and reduces ventricular arrhythmias in a swine model of acute myocardial infarction. Pharmacol Res 57: 43–48.
121. Novak J, Danielson LA, Kerchner LJ, Sherwood OD, Ramirez RJ, Moalli PA et al. (2001). Relaxin is essential for renal vasodilation during pregnancy in conscious rats. J Clin Invest 107: 1469–1475.
122. Osheroff PL, Cronin MJ, Lofgren JA (1992). Relaxin binding in the rat heart atrium. Proc Natl Acad Sci U S A 89: 2384–2388.
123. Parikh A, Patel D, McTiernan CF, Xiang W, Haney J, Yang L et al. (2013). Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts. Circ Res 113: 313–321.
124. Paulus WJ, Tschope C (2013). A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62: 263–271.
125. Peschel T, Schonauer M, Thiele H, Anker SD, Schuler G, Niebauer J (2003). Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail 5: 609–614.
126. Ponikowski P, Mitrovic V, Ruda M, Fernandez A, Voors AA, Vishnevsky A et al. (2014). A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J 35: 431–441.
127. Quattrone S, Chiappini L, Scapagnini G, Bigazzi B, Bani D (2004). Relaxin potentiates the expression of inducible nitric oxide synthase by endothelial cells from human umbilical vein in in vitro culture. Mol Hum Reprod 10: 325–330.
128. Samuel CS, Bodaragama H, Chew JY, Widdop RE, Royce SG, Hewitson TD (2014). Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease. Hypertension 64: 315–322.
129. Samuel CS, Cendrawan S, Gao XM, Ming Z, Zhao C, Kiriazis H et al. (2011). Relaxin remodels fibrotic healing following myocardial infarction. Lab Invest 91: 675–690.
130. Samuel CS, Hewitson TD, Zhang Y, Kelly DJ (2008). Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy. Endocrinology 149: 3286–3293.
131. Samuel CS, Lekgabe ED, Mookerjee I (2007). The effects of relaxin on extracellular matrix remodeling in health and fibrotic disease. Adv Exp Med Biol 612: 88–103.
132. Samuel CS, Parry LJ, Summers RJ (2003). Physiological or pathological–a role for relaxin in the cardiovascular system? Curr Opin Pharmacol 3: 152–158.
133. Samuel CS, Unemori EN, Mookerjee I, Bathgate RA, Layfield SL, Mak J et al. (2004a). Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 145: 4125–4133.
134. Samuel CS, Zhao C, Bond CP, Hewitson TD, Amento EP, Summers RJ (2004b). Relaxin-1-deficient mice develop an age-related progression of renal fibrosis. Kidney Int 65: 2054–2064.
135. Sarwar M, Samuel CS, Bathgate RA, Stewart DR, Summers RJ (2016). Enhanced serelaxin signalling in co-cultures of human primary endothelial and smooth muscle cells. Br J Pharmacol 173: 484–496.
136. Sarwar M, Samuel CS, Bathgate RA, Stewart DR, Summers RJ (2015). Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration–response curves reflect differential coupling to G proteins. Br J Pharmacol 172: 1005–1019.
137. Sasser JM, Molnar M, Baylis C (2011). Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(omega)-nitro-l-arginine methyl ester hypertensive rats. Hypertension 58: 197–204.
138. Sato N, Takahashi W, Hirayama A, Ajioka M, Takahashi N, Okishige K et al. (2015). Multicenter, randomized, double-blinded, placebo-controlled phase II study of serelaxin in Japanese patients with acute heart failure. Circ J 79: 1237–1247.
139. Segal MS, Sautina L, Li S, Diao Y, Agoulnik AI, Kielczewski J et al. (2012). Relaxin increases human endothelial progenitor cell NO and migration and vasculogenesis in mice. Blood 119: 629–636.
140. Shaw EE, Wood P, Kulpa J, Yang FH, Summerlee AJ, Pyle WG (2009). Relaxin alters cardiac myofilament function through a PKC-dependent pathway. Am J Physiol Heart Circ Physiol 297: H29–H36.
141. Sherwood OD (2004). Relaxin's physiological roles and other diverse actions. Endocr Rev 25: 205–234.
142. Slangen BF, Out IC, Verkeste CM, Peeters LL (1996). Hemodynamic changes in early pregnancy in chronically instrumented, conscious rats. Am J Physiol 270: H1779–H1784.
143. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 44 (Database Issue): D1054–D1068.
144. Stangl K, Dschietzig T, Richter C, Laule M, Stangl V, Tanis E et al. (2000). Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure: acute effects of vasodilator therapy. Circulation 102: 1132–1138.
145. Tan YY, Wade JD, Tregear GW, Summers RJ (1999). Quantitative autoradiographic studies of relaxin binding in rat atria, uterus and cerebral cortex: characterization and effects of oestrogen treatment. Br J Pharmacol 127: 91–98.
146. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH et al. (2013). Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381: 29–39.
147. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD et al. (2009). Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373: 1429–1439.
148. Toth M, Taskinen P, Ruskoaho H (1996). Relaxin stimulates atrial natriuretic peptide secretion in perfused rat heart. J Endocrinol 150: 487–495.
149. Unemori EN, Erikson ME, Rocco SE, Sutherland KM, Parsell DA, Mak J et al. (1999). Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women. Hum Reprod 14: 800–806.
150. Unemori EN, Ferrara N, Bauer EA, Amento EP (1992). Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 153: 557–562.
151. Unemori EN, Lewis M, Constant J, Arnold G, Grove BH, Normand J et al. (2000). Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regen 8: 361–370.
152. Unemori EN, Pickford LB, Salles AL, Piercy CE, Grove BH, Erikson ME et al. (1996). Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 98: 2739–2745.
153. Vodstrcil LA, Shynlova O, Westcott K, Laker R, Simpson E, Wlodek ME et al. (2010). Progesterone withdrawal, and not increased circulating relaxin, mediates the decrease in myometrial relaxin receptor (RXFP1) expression in late gestation in rats. Biol Reprod 83: 825–832.
154. Voors AA, Dahlke M, Meyer S, Stepinska J, Gottlieb SS, Jones A et al. (2014). Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study. Circ Heart Fail 7: 994–1002.
155. Voors AA, Davison B, Felker GM, Ponikowski P, Unemori E, Cotter G et al. (2011). Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. Eur J Heart Fail 13: 961–967.
156. Webb DJ (1995). Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Endothelin antagonism in heart failure. Circulation 92: 3372.
157. Williams EJ, Benyon RC, Trim N, Hadwin R, Grove BH, Arthur MJ et al. (2001). Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut 49: 577–583.
158. Wilson BC, Connell B, Saleh TM (2006). Relaxin-induced reduction of infarct size in male rats receiving MCAO is dependent on nitric oxide synthesis and not estrogenic mechanisms. Neurosci Lett 393: 160–164.
159. Xu Q, Chakravorty A, Bathgate RA, Dart AM, Du XJ (2010). Relaxin therapy reverses large artery remodeling and improves arterial compliance in senescent spontaneously hypertensive rats. Hypertension 55: 1260–1266.
160. Xu Q, Lekgabe ED, Gao XM, Ming Z, Tregear GW, Dart AM et al. (2008). Endogenous relaxin does not affect chronic pressure overload-induced cardiac hypertrophy and fibrosis. Endocrinology 149: 476–482.
161. Yan W, Chen J, Wiley AA, Crean-Harris BD, Bartol FF, Bagnell CA (2008). Relaxin (RLX) and estrogen affect estrogen receptor alpha, vascular endothelial growth factor, and RLX receptor expression in the neonatal porcine uterus and cervix. Reproduction 135: 705–712.
162. Yao L, Agoulnik AI, Cooke PS, Meling DD, Sherwood OD (2009). Relative roles of the epithelial and stromal tissue compartment(s) in mediating the actions of relaxin and estrogen on cell proliferation and apoptosis in the mouse lower reproductive tract. Ann N Y Acad Sci 1160: 121–129.
163. Yoshida T, Kumagai H, Kohsaka T, Ikegaya N (2013). Relaxin protects against renal ischemia–reperfusion injury. Am J Physiol Renal Physiol 305: F1169–F1176.
164. Yoshida T, Kumagai H, Suzuki A, Kobayashi N, Ohkawa S, Odamaki M et al. (2011). Relaxin ameliorates salt-sensitive hypertension and renal fibrosis. Nephrol Dial Transplant 27: 2190–2197.
165. Zhang J, Qi YF, Geng B, Pan CS, Zhao J, Chen L et al. (2005). Effect of relaxin on myocardial ischemia injury induced by isoproterenol. Peptides 26: 1632–1639.
166. Zhang Q, Liu SH, Erikson M, Lewis M, Unemori E (2002). Relaxin activates the MAP kinase pathway in human endometrial stromal cells. J Cell Biochem 85: 536–544.
167. Zhang X, Ma X, Zhao M, Zhang B, Chi J, Liu W et al. (2015). H2 and H3 relaxin inhibit high glucose-induced apoptosis in neonatal rat ventricular myocytes. Biochimie 108: 59–67.
168. Zhao L, Roche PJ, Gunnersen JM, Hammond VE, Tregear GW, Wintour EM et al. (1999). Mice without a functional relaxin gene are unable to deliver milk to their pups. Endocrinology 140: 445–453.
169. Zhao L, Samuel CS, Tregear GW, Beck F, Wintour EM (2000). Collagen studies in late pregnant relaxin null mice. Biol Reprod 63: 697–703.